Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Benidipine Hydrochloride.
- Who it may be relevant to
- Registry conditions: Chronic Coronary Syndrome, Hypertension, Angina Pectoris. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of Clinical Outcomes of Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients in the Turkish Population
Overview
Evaluation of the clinical outcomes of Benidipine initiated by physician's preference in patients with hypertension and/or angina pectoris (chronic coronary syndrome) presenting to cardiology outpatient clinics in Turkey.
Detailed description
* Benidipine is a dihydropyridine calcium channel blocker used in the treatment of hypertension and angina pectoris. There are currently no large-scale observational studies in these patient groups in Turkey. * There is no record of benidipine in clinicaltrials.gov, which is an important database especially for the registration of drug and interventional studies. * Therefore, it will be extremely important to include this study in clinicaltrials.gov and to evaluate the clinical efficacy of Bendipine in patients with hypertensive and/or angina pectoris in 7 geographical regions of Turkey.
Interventions
- Drug Benidipine Hydrochloride
The safety and efficacy of a dihydropyridine calcium channel blocker for the treatment of high blood pressure and/or angina pectoris
Primary outcome measures
- The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85 [Time frame: 3 months]
- Change in angina symptom severity as measured by the Seattle Angina Questionnaire score from baseline to the end of study [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Patients with hypertension and/or angina pectoris on the background of chronic coronary syndrome who have been receiving Benidipine treatment for at least 1 month and will continue to receive Benidipine treatment
- Male or female outpatients, 18-80 years of age
- Patients with mild to moderate essential hypertension who have been receiving or will continue Benidipine treatment for at least 1 month
- Outpatients with clinically stable angina pectoris and patients who have been receiving or will continue Benidipine treatment for at least 1 month
- Those who signed the written informed consent form
Exclusion criteria
- Patients with secondary hypertension
- Emergency hypertensive patients
- Having to take other medications during the study that may affect blood pressure
- Allergic to DHP calcium antagonists
- Evidence of decompensated congestive heart failure, unstable angina or severe arrhythmia
- Severe renal or hepatic dysfunction
- Pregnant or lactating women
- Participation in other clinical trials within 3 months prior to this study
- Patients who did not sign the consent form of the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Turkey (Türkiye) · 1 center
- Antalya Kepez State Hospital — Antalya
Identifiers
NCT: NCT06808321 · 2025-01